Kura Oncology Inc. (KURA): H.C. Wainwright Sees 379% Upside Potential and Points out Study Progress!
Reading Time: 3 minutes
Kura Oncology Inc. (KURA) is a biotech company focusing on the development of precision medicines for the treatment of cancer. The company specializes in small molecules that target specific signaling pathways in cancer cells to improve treatment outcomes. Among the developments, Ziftomenib, a menin inhibitor being developed for the treatment of acute myeloid leukemia (AML) with NPM1 mutations, is considered to be particularly significant. Currently, Ziftomenib is in a registration-directed study that has achieved the primary endpoint of complete...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
